NCT03654768 2025-12-18
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Active not recruiting
SWOG Cancer Research Network
Children's Oncology Group
Ascentage Pharma Group Inc.
UNC Lineberger Comprehensive Cancer Center
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center